This topic contains a solution. Click here to go to the answer

Author Question: A client in renal failure who has had hourly urinary output of 15 mL/hour and then has an increase ... (Read 33 times)

chandani

  • Hero Member
  • *****
  • Posts: 541
A client in renal failure who has had hourly urinary output of 15 mL/hour and then has an increase to 60 mL/hour would most probably need:
 a. a fluid restriction.
  b. electrolyte replacement.
  c. an increase in protein in the diet.
  d. a sodium restriction of 2-3 grams daily.

Question 2

To control hyperphosphatemia in chronic renal failure, an intervention would be to:
 a. increase dairy products.
  b. increase protein intake.
  c. administer a phosphate binder.
  d. restrict calcium supplements.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

sierramartinez

  • Sr. Member
  • ****
  • Posts: 313
Answer to Question 1

b

Answer to Question 2

c




chandani

  • Member
  • Posts: 541
Reply 2 on: Aug 2, 2018
Great answer, keep it coming :)


coreycathey

  • Member
  • Posts: 333
Reply 3 on: Yesterday
YES! Correct, THANKS for helping me on my review

 

Did you know?

The tallest man ever known was Robert Wadlow, an American, who reached the height of 8 feet 11 inches. He died at age 26 years from an infection caused by the immense weight of his body (491 pounds) and the stress on his leg bones and muscles.

Did you know?

Blood is approximately twice as thick as water because of the cells and other components found in it.

Did you know?

In inpatient settings, adverse drug events account for an estimated one in three of all hospital adverse events. They affect approximately 2 million hospital stays every year, and prolong hospital stays by between one and five days.

Did you know?

Eating food that has been cooked with poppy seeds may cause you to fail a drug screening test, because the seeds contain enough opiate alkaloids to register as a positive.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library